Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan diabetes clinical data management study group (JDDM23)

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 787-797

  Oishi, M ^a   Abe, N ^b   Yokoyama, H ^c   Kuribayashi, N ^d   Tomonaga, O ^e   Matoba, K ^f   Kobayashi, M ^g  

^a Oishi Clinic   (Japan)

^b Abe Diabetes Clinic   (Japan)

^c Jiyugaoka Yokoyama Internal Medicine Clinic   (Japan)

^d Misaki Internal Medicine Clinic   (Japan)

^e Tomonaga Clinic   (Japan)

^f Matoba Diabetes Clinic   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Insulin Detemir; Neutral Protamine Hagedorn (NPH) Insulin; Nocturnal Quality Of Life; Open Label Study; Type 2 Diabetes Mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; WELLBEING;

EID: 84860449488     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000245     Document Type: Article

References (27)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
3. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
4. Sreenan S, Virkamäki A, Zhang K, et al: Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract 2008; 62: 1971-1980.
5. Haak T, Tiengo A, Draeger E, et al: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared with NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
6. Russell-Jones D, Simpson R, Hylleberg B, et al: Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
7. Hermansen K, Fontaine P, Kukolja KK, et al: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
8. Kobayashi M, Iwamoto Y, Kaku K, et al: 48-week randomized multicenter open-label parallel group phase 3 trial to compare insulin detemir and NPH insulin efficacy and safety in subjects with insulin-requiring diabetes mellitus in a basal-bolus regimen. J Jpn Diabetes Soc 2007; 50: 649-663 [in Japanese, English abstract].
9. Kobayashi M, Yamazaki K, Hirao K, et al: The status of diabetes control and antidiabetic drug therapy in Japan - a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198-204.
10. Ministry of Welfare, Labour and Health: Guidelines for Epidemiological Studies in Japan (available at: http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ekigaku/0504sisin.html).
11. Ishii H, Furuya M, Iburi T, et al: Insulin therapy related QOL at night (ITR-QOLN). J Jpn Diabetes Soc 2008; 51: 593-600 [in Japanese, English abstract].
12. Ishii H, Furuya M, Iburi T, et al: Quality of life in insulin-treated patients. J Jpn Diabetes Soc 2008; 51: 601-608 [in Japanese, English abstract].
13. Ishii H, Iwamoto Y, Kaku K, et al: Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy - randomized multicenter open-label parallel group phase 3 trial compared with NPH insulin. J Jpn Diabetes Soc 2009; 52: 691-701 [in Japanese, English abstract].
14. Plank J, Bodenlenz M, Sinner F, et al: A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.
15. Porcellati F, Bolli GB, Fanelli CG: Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 2011; 13(suppl 1): S15-S24.
16. Fontaine P, Gin H, Pinget M, et al: Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv Ther 2009; 26: 535-551.
17. Le Floch JP, Lévy M, Mosnier-Pudar H, et al: Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009; 32: 32-37.
18. Hermansen K, Davies M, Derezinski T, et al: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
19. De Leeuw I, Vague P, Selam JL, et al: Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
20. Pieber TR, Treichel HC, Hompesch B, et al: Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635-642.
21. Bartley PC, Bogoev M, Larsen J, et al: Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25: 442-449.
22. Pontiroli AE, Miele L, Morabito A: Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011; 13: 1008-1019.
23. Hermansen K, Mortensen LS: Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-1142.
24. Campbell IW: Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract 2010; 64: 791-801.
25. Zachariah S, Sheldon B, Shojaee-Moradie F, et al: Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care 2011; 34: 1487-1491.
26. Hennige AM, Sartorius T, Tschritter O, et al: Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274-1282.
27. Woods SC, D'Alessio DA: Central control of body weight and appetite. J Clin Endocrinol Metab 2008; 93(11 suppl 1): S37-S50.